Navigation Links
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

LONDON, 12 July 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces new data from its phase II trial of ASA404 in recurrent, platinum-sensitive ovarian cancer. This trial compares patients receiving ASA404 plus chemotherapy (n=37) with patients receiving chemotherapy alone (n=38). The main findings are as follows:

* There was no advantage in median time to tumour progression in the ASA404 arm compared with the control arm * One-year survival rates were 74% for the ASA404 arm and 92% for the control arm. Since the majority of patients in both arms were alive after one year, median survival values have not been determined * Independently-determined response rates were consistent with those previously reported from investigator assessment and showed a higher response rate in the ASA404 arm * Addition of ASA404 to chemotherapy was generally well tolerated.

Based on these data, development in ovarian cancer will not be a priority.

Antisoma has been testing ASA404 in several cancer types and previously reported a 5-month increase in median survival when the drug was added to chemotherapy in non-small cell lung cancer.

Antisoma licensed ASA404 to Novartis in April 2007. Novartis plans to start enrolling patients into a phase III trial in non-small cell lung cancer early in 2008 and to explore the potential benefits of the compound in various other solid tumours.

Glyn Edwards, Antisoma's CEO said, "Our ovarian cancer trial has not produced positive results like those seen with ASA404 in lung cancer. More broadly, we're very pleased with the progress made by Novartis to date with ASA404 in lung cancer and look forward to working with them to fully evaluate the drug in other cancers."

Enquiries: Glyn Edwards, Chief Executive Officer Daniel Elger, Director of Communications +44 (0) 7909 915068 Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Sky
'"/>




Page: 1 2 3

Related medicine technology :

1. Data supporting three Antisoma programmes presented at AACR
2. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
(Date:7/28/2014)... , July 28, 2014  Surgical Theater, ... members to its Business Advisory Board. New members ... Vice President for Business Development and New Technologies ... Fulton , former Senior Vice President and General ... Surgical Theater applies flight simulation technology to brain ...
(Date:7/28/2014)... , July 28, 2014  UBM Medica US ... leading online community for medical imaging professionals, explored the ... value-based payment models . The shift from ... how the radiologist,s reimbursement is determined in the ... insight from leaders in the field, who recognized the ...
(Date:7/28/2014)... 2014  A prospective study conducted by the ... has validated the performance of VolparaDensity breast imaging ... volumetrically assessed breast density measurements to breast cancer ... Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated measurement ... breast cancer risk assessment," was authored by ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Diagnostic Imaging Delves into Measuring the Radiologist's Value 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... 19, 2011 Reportlinker.com announces that a ... its catalogue: European Medical ... This research service examines ... terms of the challenges faced by market ...
... July 19, 2011 Data were presented today from ... including data from a 32 week follow-up period after ... gamma secretase inhibitor that had been studied as a ... patient outcomes from the active treatment portion of the ...
Cached Medicine Technology:European Medical Displays Markets 2European Medical Displays Markets 3European Medical Displays Markets 4Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 2Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 3Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 4
(Date:7/28/2014)... Dotinga HealthDay Reporter MONDAY, ... humans just milliseconds to look at someone,s face and judge ... finds that certain facial features seem to trigger specific first ... size of the mouth, for example, appear directly linked to ... attractiveness. The study findings suggest that first impressions ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Ticket Down ... AS Roma tickets in Dallas, TX at the Cotton ... 24th in the USA and it is an eight team ... around the world including teams from La Liga, Serie A, ... that will battle it out on the pitch include: ...
(Date:7/28/2014)... NY (PRWEB) July 28, 2014 Glutamine ... body and it’s considered to be conditionally essential during ... and is an advanced recovery & Immune System Support. ... the glutamine your body produces, supplementing with additional glutamine ... of waste products in the body, digestion and immune ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... are at risk of contracting meningitis because of specific ... to updated recommendations from the largest pediatrician group in ... the potentially deadly infection should continue for adolescents and ... In its first statement on meningococcal vaccines since 2011, ...
(Date:7/28/2014)... 2014 (HealthDay News) -- Endurance runners are far more ... heart condition, according to a new study. ... events in warm climates are actually 10 times more ... the less common sudden death of a young and ... as an irregular heartbeat, often gets a lot more ...
Breaking Medicine News(10 mins):Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2
... with Frequently ... Misdiagnosed Condition, WASHINGTON, ... (IC) Awareness Day, the National Association of Nurse,Practitioners in Women,s ... released the results of the first survey of IC,patients highlighting ...
... Funding will Accelerate Expansion of Industry Leading Health and Human ... Services On-Demand Software Solutions, ... the industry-leading provider of software solutions for the,health and human ... equity and debt financing totaling $28 million. The round was ...
... seasonal * Online advertised vacancies are ... the year gains in advertised ... vacancies, * ... 31 In October there were 4,161,700,online advertised vacancies, a decrease of 108,300 ...
... even Alzheimer,s, experts say , , WEDNESDAY, Oct. 31 (HealthDay News) ... brain,s own stem cells may have the ability to restore ... by protecting existing cells and promoting neuronal connections. , In ... were able to bring the rodents, memory back to healthy ...
... seventh leading cause of cancer death worldwide, the occurrence ... and gender. Esophageal cancer is thought to be triggered ... the host genome. Researchers have long been seeking the ... on gene-environment interaction and gene polymorphisms for esophageal cancer. ...
... undertaking elective surgery to remove part or all of the ... be too high, warn researchers in a study published on ... term for chronic inflammation of the intestine and includes ulcerative ... people in the UK are affected and many people will ...
Cached Medicine News:Health News:October 31 is National Interstitial Cystitis (IC) Awareness Day 2Health News:October 31 is National Interstitial Cystitis (IC) Awareness Day 3Health News:October 31 is National Interstitial Cystitis (IC) Awareness Day 4Health News:Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank 2Health News:Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank 3Health News:Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank 4Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 2Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 3Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 4Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 5Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 6Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Threshold for bowel surgery may be too high, warn experts 2
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Medicine Products: